Sympathetic overdrive and cardiovascular risk in the metabolic syndrome

Hypertension Research

Volumn 29, Issue 11, 2006, Pages 839-847

  Grassi, Guido ^a,b,c  

^a SAN GERARDO HOSPITAL   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Antihypertensive drugs; Hypertension; Metabolic syndrome; Obesity; Sympathetic nervous system

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CILNIDIPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMIDAZOLINE; INSULIN; LEPTIN; MEPIRODIPINE; MONOXIDINE; RILMENIDINE; UNCLASSIFIED DRUG;

ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; BLOOD PRESSURE REGULATION; CALORIC RESTRICTION; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENERGY BALANCE; EVIDENCE BASED MEDICINE; HEART HYPERTROPHY; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; OBESITY; ORGAN INJURY; PATHOGENESIS; PATHOPHYSIOLOGY; PRESSORECEPTOR REFLEX; PROGNOSIS; REVIEW; RISK REDUCTION; SLEEP APNEA SYNDROME; SYMPATHETIC BLOCKING; VASCULAR DISEASE;

CARDIOVASCULAR SYSTEM; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; SYMPATHETIC NERVOUS SYSTEM;

EID: 33846108745     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.839     Document Type: Review

References (76)

1. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.
2. Morrison SF: Central pathways controlling brown adipose tissue thermogenesis. News Physiol Sci 2004; 19: 67-74.
3. Grassi G: Role of the sympathetic nervous system in human hypertension. J Hypertens 1998; 16: 1979-1987.
4. Grassi G, Mancia G: Neurogenic hypertension: is the enigma of its origin near the solution? Hypertension 2004; 43: 154-155.
5. Amerena J, Julius S: The role of the autonomic nervous system in hypertension. Hypertens Res 1995; 18: 99-110.
6. Julius S, Krause L, Schork NJ, et al: Hyperkinetic borderline hypertension in Tecumseh, Michigan. Hypertension 1991; 9: 77-84.
7. Grassi G, Mancia G: The function of the autonomic nervous system in hypertension, in Bolis L, Licinio J, Govoni S (eds): Handbook of the Autonomic Nervous System. New York, Marcel Dekker, 2003, pp 425-438.
8. Grassi G, Vailati S, Bertinieri G, et al: Heart rate as marker of sympathetic activity. J Hypertens 1998; 16: 1635-1639.
9. Grassi G, Esler M: How to assess sympathetic activity in humans. J Hypertens 1999; 17: 719-734.
10. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G: Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998; 31: 68-72.
11. Grassi G, Seravalle G, Bertinieri G, et al: Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. J Hypertens 2000; 18: 587-593.
12. Greenwood JP, Scott EM, Stoker JB, Mary DA: Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol 2001; 38: 1711-1717.
13. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD: Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108: 560-565.
14. Esler M, Ferrier C, Lambert G, Eisenhofer G, Cox H, Jennings G: Biochemical evidence of sympathetic hyperactivity in human hypertension. Hypertension 1991; 17: S29-S35.
15. Ferrier C, Esler MD, Eisenhofer G, et al: Increased norepinephrine spillover into the jugular veins in essential hypertension. Hypertension 1992; 19: 62-69.
16. Young JB, Macdonald IA: Sympathoadrenal activity in human obesity: heterogeneity of findings since 1980. Int J Obes Relat Metab Disord 1992; 16: 959-967.
17. Troisi RJ, Weiss ST, Parker DR, Sparrow D, Young JB, Landsberg L: Relation of obesity and diet to sympathetic nervous system activity. Hypertension 1991; 17: 669-677.
18. Grassi G, Seravalle G, Cattaneo BM, et al: Sympathetic activation in obese normotensive subjects. Hypertension 1995; 25: 560-563.
19. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M: Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 1997; 96: 3423-3429.
20. Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G: Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004; 22: 2363-2369.
21. Alvarez GE, Ballard TP, Beske SD, Davy KP: Subcutaneous obesity is not associated with sympathetic neural activation. Am J Physiol 2004; 287: H414-H418.
22. Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK: Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998; 98: 772-776.
23. Grassi G, Facchini A, Trevano FQ, et al: Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 2005; 46: 321-325.
24. Grassi G, Seravalle G, Dell'Oro R, Turri C, Bolla GB, Mancia G: Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000; 36: 538-542.
25. Brunner EJ, Hemingway H, Walker BR, et al: Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 2002; 106: 2659-2665.
26. Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ: Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab 2005; 90: 5998-6005.
27. Huggett RJ, Burns J, Mackintosh AF, Mary DA: Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension 2004; 44: 847-852.
28. Grassi G, Dell'Oro R, Quarti-Trevano F, et al: Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 2005; 48: 1359-1365.
29. Arenare F, Quarti Trevano F, Dell'Oro R, et al: Metabolic syndrome potentiates the sympathetic and baroreflex dysfunction of heart failure state. J Hypertens 2006; 24: S6 (Abstract).
30. Grassi G, Giannattasio C, Cleroux J, et al: Cardiopulmonary reflex before and after regression of left ventricular hypertrophy in essential hypertension. Hypertension 1988; 12: 227-237.
31. Narkiewicz K, van de Borne PJ, Pesek CA, Dyken ME, Montano N, Somers VK: Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea. Circulation 1999; 99: 1183-1189.
32. Landsberg L: Obesity and the insulin resistance syndrome. Hypertens Res 1996; 19: S51-S55.
33. Egan BM: Insulin resistance and the sympathetic nervous system. Curr Hypertens Rep 2003; 5: 247-254.
34. Anderson EA, Balon TW, Hoffman RP, Sinkey CA, Mark AL: Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension 1992; 19: 621-627.
35. Scherrer U, Sartori C: Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997; 96: 4104-4113.
36. Grassi G, Seravalle G, Quarti Trevano F, et al: Potentiating effects of the metabolic syndrome on the sympathetic abnormalities characterizing human obesity. J Hypertens 2005; 23: S266 (Abstract).
37. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO: Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993; 21: 618-623.
38. Li YF, Wang W, Mayhan WG, Patel KP: Angiotensin-mediated increase in renal sympathetic nerve discharge within the PVN: role of nitric oxide. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1035-R1043.
39. Taddei S, Grassi G: Angiotensin II as the link between nitric oxide and neuroadrenergic function. J Hypertens 2005; 23: 935-937.
40. Grassi G: Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. J Hypertens 2001; 19: 1713-1716.
41. Grassi G, Seravalle G, Dell'Oro R, et al: CROSS Study. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21: 1761-1769.
42. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ: Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14: 425-430.
43. Grassi G, Cattaneo BM, Seravalle G, et al: Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997; 96: 1173-1179.
44. Grassi G: Leptin, sympathetic nervous system, and baroreflex function. Curr Hypertens Rep 2004; 6: 236-240.
45. Rahmouni K, Correia ML, Haynes WG, Mark AL: Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45: 9-14.
46. Cohn JN, Levine TB, Olivari MT, et al: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823.
47. Rouleau JL, Packer M, Moye L, et al: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24: 583-591.
48. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM: Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J 2001; 22: 1136-1143.
49. Gerson MC, McGuire N, Wagoner LE: Sympathetic nervous system function as measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy. J Card Fail 2003; 9: 384-391.
50. Bristow MR, Krause-Steinrauf H, Nuzzo R, et al: Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation 2004; 110: 1437-1442.
51. Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B: Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J 2005; 26: 906-913.
52. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B: Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke. Neurology 2001; 57: 833-838.
53. Copie X, Hnatkova K, Staunton A, Fei L, Camm AJ, Malik M: Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a two-year follow-up study. J Am Coll Cardiol 1996; 27: 270-276.
54. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ, ATRAMI (Autonomic Tone and Reflexes after Myocardial Infarction) Investigators: Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998; 351: 478-484.
55. Benedict CR, Shelton B, Johnstone DE, SOLVD Investigators: Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996; 94: 690-697.
56. Endo A, Kinugawa T, Ogino K, et al: Cardiac and plasma catecholamine responses to exercise in patients with type 2 diabetes: prognostic implications for cardiac-cerebrovascular events. Am J Med Sci 2000; 320: 24-30.
57. Zoccali C, Mallamaci F, Parlongo S, et al: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-1359.
58. Mancia G, Sega R, Cesana GC, et al: Metabolic syndrome in PAMELA population: prevalence, prognostic value, out-of-office blood pressures and cardiac damage. J Hypertens 2005; 23: S134 (Abstract).
59. Sen S, Tarazi RC, Khairallah PA, Bumpus FM: Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res 1974; 35: 775-781.
60. Patel MB, Stewart JM, Loud AV, et al: Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation 1991; 84: 2091-2100.
61. Kelm M, Schafer S, Mingers S, et al: Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens 1996; 14: 1357-1364.
62. Zoccali C, Mallamaci F, Tripepi G, et al: Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40: 41-46.
63. Seo HS, Kang TS, Park S, et al: Insulin resistance is associated with arterial stiffness in nondiabetic hypertensives independent of metabolic status. Hypertens Res 2005; 28: 945-951.
64. Grassi G, Giannattasio C, Failla M, et al: Sympathetic modulation of radial artery compliance in congestive heart failure. Hypertension 1995; 26: 348-354.
65. Grassi G, Giannattasio C: Obesity and vascular stiffness: when body fat has an adverse impact on arterial dynamics. J Hypertens 2005; 23: 1789-1791.
66. De Backer G, Ambrosioni E, Borch-Johnsen K, et al: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-1610.
67. European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
68. Grundy SM, Cleeman JI, Daniels SR, et al: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
69. Takeuchi H, Saitoh S, Takagi S, et al: Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men - the Tanno and Sobetsu Study. Hypertens Res 2005; 28: 203-208.
70. Palatini P, Benetos A, Grassi G, et al: Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006; 24: 603-610.
71. Grassi G, Seravalle G, Colombo M, et al: Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998; 97: 2037-2042.
72. Grassi G, Seravalle G, Calhoun DA, Mancia G: Physical training and baroreceptor control of sympathetic nerve activity in humans. Hypertension 1994; 23: 294-301.
73. Iwane M, Arita M, Tomimoto S, et al: Walking 10,000 steps/day or more reduces blood pressure and sympathetic nerve activity in mild essential hypertension. Hypertens Res 2000; 23: 573-580.
74. Grassi G: Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens 2004; 13: 513-519.
75. Grassi G: Neuroadrenergic effects of calcium channel blockers: a developing concept. J Hypertens 2004; 22: 887-888.
76. 1-receptor agonists: do they have a place in the management of hypertension? Am J Cardiovasc Drugs 2001; 1: 321-326.